Shareholders of RBT (Biotechnology Development JSC) have decided to increase the authorized capital through an additional share issue to attract investments for the updated strategy.
The Company plans to place the additional issue via private subscription and raise approximately RUB 60 million in the first half of 2026. The Board of Directors of RBT has set the placement price at RUB 130 per share.
According to Igor Viktorovich Krasilnikov, Director of RBT: "The Company is raising funds to implement its updated medium-term strategy aimed at the further development of the vaccine segment, the launch of new products, the minimization of external risks, and the reduction of dependence on third-party suppliers. The Company also plans to make more active use of the licensing business model and co-development of products."
According to the updated strategy announced in November 2025, the vaccine segment remains a priority for the Company, as it is in this area that the Company possesses key competencies. RBT's portfolio includes three vaccines at an advanced stage of development: TetraFluBet (influenza), Betuvax-Cov-2 (coronavirus), and a combined coronavirus and influenza vaccine. The Company is focused on the further development of these vaccines and will seek partners to continue their development under a licensing model.
RBT will focus, inter alia, on developing new vaccines for which it will not depend on third-party partners or antigen suppliers. In 2025, RBT launched the development of a vaccine against respiratory syncytial virus (RSV).
RBT will develop a line of high-margin projects in the field of animal vaccines. This segment features a simpler regulatory pathway and will allow the Company to generate revenue more quickly.
Furthermore, RBT plans to develop contract manufacturing of medical devices at the Company's pilot production facility in the Perm Region, which will significantly reduce product time-to-market and provide the Company with financial stability.
In 2025, RBT began developing: an organ preservation solution (a medical device), a cancer vaccine for companion animals, and an adjuvant for veterinary vaccines.
In 2025, VISUS LAB successfully completed the development and registration of the innovative eyelid hygiene gel "Blepharosept" as a cosmetic product. The product contains RBT's innovative form of betulin, "Betusphere". "Blepharosept" is currently being prepared for launch into retail chains.
RBT is a resident of Skolkovo and MedTech Technopark. RBT shares are available for trading on the Over-The-Counter (OTC) market of the Moscow Exchange. Ticker: RBTY. With the support of its industrial partner Artgen Biotech and its ecosystem, RBT is developing a platform for creating effective vaccines based on surface antigens and an original corpuscular adjuvant.